Virtual Library

Start Your Search

N. Morisita



Author of

  • +

    P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Small Cell Lung Cancer
    • Presentations: 1
    • +

      P3.07-009 - The Retrospective Analysis of Nab-Paclitaxel Regimens for Relapsed Small Cell Lung Cancer Patients (ID 1384)

      09:30 - 09:30  |  Author(s): N. Morisita

      • Abstract
      • Slides

      Background:
      Although small cell lung cancer (SCLC) is initially chemo sensitive, most patients rapidly relapse. Prognosis of late line treatment for relapsed SCLC patients is generally poor. The efficacy of paclitaxel regimens for relapsed SCLC patients has been reported in some articles. But no specific study has been reported to our knowledge, about nab-paclitaxel administration for relapsed SCLC patients.

      Methods:
      By using the database of two hospitals, we underwent a retrospective analysis to evaluate the efficacy and safety of nab-paclitaxel regimens for relapsed SCLC patients. The data of patient characteristics, treatment efficacy and adverse events were collected from the medical records.

      Results:
      Fourteen patients (3 women and 11 men) with relapsed SCLC were administered weekly nab-paclitaxel or carboplatin plus nab-paclitaxel between February 2013 and July 2014 in our hospitals. The median age was 71 years old. Eight patients had comorbid pulmonary disease (5 had interstitial lung disease, 2 had chronic obstructive pulmonary disease, and 1 had both diseases). Five patients were administered nab-paclitaxel regimen as second line chemotherapy, five patients were as third line and four patients were as fourth or fifth line. Five patients achieved partial response, and four patients had stable disease. The response rate was 36%, and disease control rate was 64%. Most common toxicities were hematological adverse events such as neutrophil count and anemia. Severe neutropenia (Grade 3 or 4) appeared to some patients, but all patients were restored by treatment. The main non-hematologic adverse events were neurotoxicity and constipation, and these events were mild.

      Conclusion:
      The administration of nab-paclitaxel regimens to highly treated patients with relapsed SCLC demonstrated modest response rate and disease control rate. All adverse events were manageable, so that nab-paclitaxel regimens were well tolerated. Further clinical trial to evaluate the efficacy and safety of nab-paclitaxel regimens for relapsed SCLC patients is warranted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.